TherapeuticsMD, Inc. (NASDAQ:TXMD) Short Interest Update

TherapeuticsMD, Inc. (NASDAQ:TXMD) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 240,200 shares, a growth of 1,901.7% from the December 31st total of 12,000 shares. Based on an average daily volume of 286,000 shares, the short-interest ratio is currently 0.8 days. Currently, 2.1% of the shares of the stock are short sold.

TherapeuticsMD Price Performance

TXMD stock remained flat at $1.08 during trading on Friday. 12,606 shares of the company traded hands, compared to its average volume of 851,383. The stock’s 50-day moving average price is $1.17 and its two-hundred day moving average price is $1.49. TherapeuticsMD has a 12 month low of $0.70 and a 12 month high of $2.75.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Tuesday, November 12th. The company reported ($0.05) earnings per share (EPS) for the quarter. TherapeuticsMD had a negative net margin of 207.77% and a negative return on equity of 14.08%. The company had revenue of $0.55 million during the quarter.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on TherapeuticsMD in a report on Tuesday, January 14th. They issued a “hold” rating for the company.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.